Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 158   

Articles published

NVS 69.74 +2.15 (3.18%)
price chart
The Biosimilar of Amgen's Enbrel, by Novartis AG (ADR) (NYSE:NVS), has been ...
In a latest development, the Food and Drug Administration (FDA) has announced the approval of Novartis AG's (NYSE:NVS) Erelzi, which is a biosimilar version of Amgen's blockbuster drug Enbrel.
Novartis AG (ADR) Enbrel Biosimilar Approved: What's Next for Amgen?  Smаrt Stоck Nеws
Amgen, Inc: How Damaging Will Be Novartis' Enbrel Copy  Bidness ETC
Novartis AG Ready to Capture Leukemia Therapeutic Market
Novartis AG (ADR) (NYSE:NVS) is putting efforts to capture the lucrative market of immuno-oncology with its investigational molecules covering multiple therapeutic areas.
Can Novartis AG (ADR) (NVS) Survive with Alcon Crisis?
Novartis AG (ADR) (NYSE:NVS) is considering the sale of its eye care division, Alcon, due to its revenue decline in the last two years.
Novartis AG (ADR) 19.3% Potential Upside Now Implied by Chardan Capital Markets
Novartis AG (ADR) using SYMBOL/TICKER code NYSE:NVS has had its stock rating noted as 'Reiterated' with the recommendation being set at 'BUY' yesterday by research analysts at Chardan Capital Markets.
Novartis AG (NVS) Seeks M&A as It Mulls Possible Alcon Sale
Novartis AG (ADR) (NYSE:NVS) is planning to enter into mergers and acquisitions as it continues to weigh options for the long-struggling eye-care business Alcon.
Novartis AG (ADR) (NYSE:NVS) To Pay $25 Million Over Bribery Allegations
Last year GlaxoSmithKline plc (ADR) (NYSE:GSK) posted a 17% drop in sales as a state-led campaign on drug prices affected returns.
Notable 13F Report: Novartis Ag Sponsored Adr (NVS) Valuation Rose While ...
Cambridge Trust Company increased its stake in Novartis Ag Sponsored Adr (NVS) by 76.95% based on its latest 2016Q2 regulatory filing with the SEC.
Bimagrumab (BYM338) drug from Novartis AG (ADR) (NYSE:NVS) Failed a Phase ...  MoneyMakingArticles
Novartis AG (ADR) (NVS) And Pfizer Inc. (PFE) Are In A Race To Gain Favor In ...
Novartis AG (ADR) (NYSE:NVS) CDK4/6 breast cancer drug remains on track with Pfizer Inc. (NYSE:PFE)'s Ibrance. The pharma giant has already obtained a regulatory pathway for its LEE011 from the FDA after going through the hurdle of priority review.
Rating Sentiment Worth Mentioning: Discussion stirs around Novartis AG (ADR ...  MoneyMakingArticles
Novartis AG (NVS) May Fancy AstraZeneca plc (AZN) for Takoever: Reports
The American depository receipts of AstraZeneca plc (ADR) (NYSE:AZN) traded up over 1% on the New York exchange Friday, after a report suggested that the company may attract a takeover interest from Novartis AG (ADR) (NYSE:NVS). Novartis' ADRs ...
Will Novartis AG (ADR) (NVS) Cosentyx Lead Psoriasis Therapeutic Market?
Keeping in view fierce competition in the future as well as the patent cliff side effects, Novartis AG (ADR) (NYSE:NVS) is working on its blockbuster molecule Cosentyx to be the market leader in the management and treatment of psoriasis.
Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY)'s CEO takes home more pay in ...  Thorold News
Will Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) And Novartis AG ...  MoneyMakingArticles